United Therapeutics Corporation $UTHR Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC reduced its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 1.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 1,200,365 shares of the biotechnology company’s stock after selling 23,628 shares during the period. Geode Capital Management LLC’s holdings in United Therapeutics were worth $344,261,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in UTHR. Chung Wu Investment Group LLC purchased a new position in shares of United Therapeutics during the second quarter worth about $29,000. SVB Wealth LLC acquired a new stake in United Therapeutics during the 1st quarter worth approximately $32,000. Geneos Wealth Management Inc. grew its stake in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Brooklyn Investment Group increased its holdings in shares of United Therapeutics by 103.2% in the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 98 shares during the period. Finally, WPG Advisers LLC purchased a new stake in shares of United Therapeutics during the first quarter worth approximately $60,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Up 0.9%

United Therapeutics stock opened at $466.40 on Friday. The firm has a market capitalization of $20.08 billion, a PE ratio of 17.67, a P/E/G ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $479.50. The firm’s 50-day simple moving average is $432.38 and its 200 day simple moving average is $349.68.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same period last year, the firm posted $6.39 EPS. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. On average, research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of analyst reports. UBS Group lifted their price objective on shares of United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Bank of America boosted their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. HC Wainwright raised their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Royal Bank Of Canada boosted their target price on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Finally, Oppenheimer increased their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $503.90.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total transaction of $9,396,900.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders have sold 471,435 shares of company stock worth $200,294,552. Company insiders own 10.30% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.